Phospholipase C-related catalytically inactive protein

A novel signaling molecule for modulating fat metabolism and energy expenditure

Takashi Kanematsu, Kana Oue, Toshiya Okumura, Kae Harada, Yosuke Yamawaki, Satoshi Asano, Akiko Mizokami, Masahiro Irifune, Masato Hirata

Research output: Contribution to journalReview article

Abstract

Background: Overweight and obesity are defined as excessive or abnormal fat accumulation in adipose tissues, and increase the risk of morbidity in many diseases, including hypertension, dyslipidemia, type 2 diabetes, coronary heart disease, and stroke, through pathophysiological mechanisms. There is strong evidence that weight loss reduces the risk of metabolic syndrome by limiting blood pressure and improving the levels of serum triglycerides, total cholesterol, low-density lipoprotein-cholesterol, and high-density lipoprotein-cholesterol. To date, several attempts have been made to develop effective anti-obesity medication or weight-loss drugs; however, satisfactory drugs for clinical use have not yet been developed. Therefore, elucidation of the molecular mechanisms driving fat metabolism (adipogenesis and lipolysis) represents the first step in developing clinically useful drugs and/or therapeutic treatments to control obesity. Highlight: In our previous study on intracellular signaling of phospholipase C-related catalytically inactive protein (PRIP), we generated and analyzed Prip-double knockout (Prip-DKO) mice. Prip-DKO mice showed tolerance against insulin resistance and a lean phenotype with low fat mass. Here, we therefore reviewed the involvement of PRIP in fat metabolism and energy expenditure. We conclude that PRIP, a protein phosphatase-binding protein, can modulate fat metabolism via phosphoregulation of adipose lipolysis-related molecules, and regulates non-shivering heat generation in brown adipocytes. Conclusion: We propose PRIP as a new therapeutic target for controlling obesity or developing novel anti-obesity drugs.

Original languageEnglish
Pages (from-to)65-72
Number of pages8
Journaljournal of oral biosciences
Volume61
Issue number2
DOIs
Publication statusPublished - Jun 1 2019

Fingerprint

Staphylococcal Protein A
Type C Phospholipases
Metabolism
Energy Metabolism
Fats
Obesity
Molecules
Anti-Obesity Agents
Lipolysis
Knockout Mice
Proteins
Brown Adipocytes
Adipogenesis
Phosphoprotein Phosphatases
Cholesterol
Blood pressure
Heat generation
Medical problems
Dyslipidemias
Protein Binding

All Science Journal Classification (ASJC) codes

  • Medicine (miscellaneous)
  • Dentistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Phospholipase C-related catalytically inactive protein : A novel signaling molecule for modulating fat metabolism and energy expenditure. / Kanematsu, Takashi; Oue, Kana; Okumura, Toshiya; Harada, Kae; Yamawaki, Yosuke; Asano, Satoshi; Mizokami, Akiko; Irifune, Masahiro; Hirata, Masato.

In: journal of oral biosciences, Vol. 61, No. 2, 01.06.2019, p. 65-72.

Research output: Contribution to journalReview article

Kanematsu, Takashi ; Oue, Kana ; Okumura, Toshiya ; Harada, Kae ; Yamawaki, Yosuke ; Asano, Satoshi ; Mizokami, Akiko ; Irifune, Masahiro ; Hirata, Masato. / Phospholipase C-related catalytically inactive protein : A novel signaling molecule for modulating fat metabolism and energy expenditure. In: journal of oral biosciences. 2019 ; Vol. 61, No. 2. pp. 65-72.
@article{3ca6b0339e49473bafe74aecde6f5817,
title = "Phospholipase C-related catalytically inactive protein: A novel signaling molecule for modulating fat metabolism and energy expenditure",
abstract = "Background: Overweight and obesity are defined as excessive or abnormal fat accumulation in adipose tissues, and increase the risk of morbidity in many diseases, including hypertension, dyslipidemia, type 2 diabetes, coronary heart disease, and stroke, through pathophysiological mechanisms. There is strong evidence that weight loss reduces the risk of metabolic syndrome by limiting blood pressure and improving the levels of serum triglycerides, total cholesterol, low-density lipoprotein-cholesterol, and high-density lipoprotein-cholesterol. To date, several attempts have been made to develop effective anti-obesity medication or weight-loss drugs; however, satisfactory drugs for clinical use have not yet been developed. Therefore, elucidation of the molecular mechanisms driving fat metabolism (adipogenesis and lipolysis) represents the first step in developing clinically useful drugs and/or therapeutic treatments to control obesity. Highlight: In our previous study on intracellular signaling of phospholipase C-related catalytically inactive protein (PRIP), we generated and analyzed Prip-double knockout (Prip-DKO) mice. Prip-DKO mice showed tolerance against insulin resistance and a lean phenotype with low fat mass. Here, we therefore reviewed the involvement of PRIP in fat metabolism and energy expenditure. We conclude that PRIP, a protein phosphatase-binding protein, can modulate fat metabolism via phosphoregulation of adipose lipolysis-related molecules, and regulates non-shivering heat generation in brown adipocytes. Conclusion: We propose PRIP as a new therapeutic target for controlling obesity or developing novel anti-obesity drugs.",
author = "Takashi Kanematsu and Kana Oue and Toshiya Okumura and Kae Harada and Yosuke Yamawaki and Satoshi Asano and Akiko Mizokami and Masahiro Irifune and Masato Hirata",
year = "2019",
month = "6",
day = "1",
doi = "10.1016/j.job.2019.04.002",
language = "English",
volume = "61",
pages = "65--72",
journal = "Journal of Oral Biosciences",
issn = "1349-0079",
publisher = "Japanese Association for Oral Biology",
number = "2",

}

TY - JOUR

T1 - Phospholipase C-related catalytically inactive protein

T2 - A novel signaling molecule for modulating fat metabolism and energy expenditure

AU - Kanematsu, Takashi

AU - Oue, Kana

AU - Okumura, Toshiya

AU - Harada, Kae

AU - Yamawaki, Yosuke

AU - Asano, Satoshi

AU - Mizokami, Akiko

AU - Irifune, Masahiro

AU - Hirata, Masato

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Background: Overweight and obesity are defined as excessive or abnormal fat accumulation in adipose tissues, and increase the risk of morbidity in many diseases, including hypertension, dyslipidemia, type 2 diabetes, coronary heart disease, and stroke, through pathophysiological mechanisms. There is strong evidence that weight loss reduces the risk of metabolic syndrome by limiting blood pressure and improving the levels of serum triglycerides, total cholesterol, low-density lipoprotein-cholesterol, and high-density lipoprotein-cholesterol. To date, several attempts have been made to develop effective anti-obesity medication or weight-loss drugs; however, satisfactory drugs for clinical use have not yet been developed. Therefore, elucidation of the molecular mechanisms driving fat metabolism (adipogenesis and lipolysis) represents the first step in developing clinically useful drugs and/or therapeutic treatments to control obesity. Highlight: In our previous study on intracellular signaling of phospholipase C-related catalytically inactive protein (PRIP), we generated and analyzed Prip-double knockout (Prip-DKO) mice. Prip-DKO mice showed tolerance against insulin resistance and a lean phenotype with low fat mass. Here, we therefore reviewed the involvement of PRIP in fat metabolism and energy expenditure. We conclude that PRIP, a protein phosphatase-binding protein, can modulate fat metabolism via phosphoregulation of adipose lipolysis-related molecules, and regulates non-shivering heat generation in brown adipocytes. Conclusion: We propose PRIP as a new therapeutic target for controlling obesity or developing novel anti-obesity drugs.

AB - Background: Overweight and obesity are defined as excessive or abnormal fat accumulation in adipose tissues, and increase the risk of morbidity in many diseases, including hypertension, dyslipidemia, type 2 diabetes, coronary heart disease, and stroke, through pathophysiological mechanisms. There is strong evidence that weight loss reduces the risk of metabolic syndrome by limiting blood pressure and improving the levels of serum triglycerides, total cholesterol, low-density lipoprotein-cholesterol, and high-density lipoprotein-cholesterol. To date, several attempts have been made to develop effective anti-obesity medication or weight-loss drugs; however, satisfactory drugs for clinical use have not yet been developed. Therefore, elucidation of the molecular mechanisms driving fat metabolism (adipogenesis and lipolysis) represents the first step in developing clinically useful drugs and/or therapeutic treatments to control obesity. Highlight: In our previous study on intracellular signaling of phospholipase C-related catalytically inactive protein (PRIP), we generated and analyzed Prip-double knockout (Prip-DKO) mice. Prip-DKO mice showed tolerance against insulin resistance and a lean phenotype with low fat mass. Here, we therefore reviewed the involvement of PRIP in fat metabolism and energy expenditure. We conclude that PRIP, a protein phosphatase-binding protein, can modulate fat metabolism via phosphoregulation of adipose lipolysis-related molecules, and regulates non-shivering heat generation in brown adipocytes. Conclusion: We propose PRIP as a new therapeutic target for controlling obesity or developing novel anti-obesity drugs.

UR - http://www.scopus.com/inward/record.url?scp=85065984451&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065984451&partnerID=8YFLogxK

U2 - 10.1016/j.job.2019.04.002

DO - 10.1016/j.job.2019.04.002

M3 - Review article

VL - 61

SP - 65

EP - 72

JO - Journal of Oral Biosciences

JF - Journal of Oral Biosciences

SN - 1349-0079

IS - 2

ER -